IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IDEAYA Biosciences Inc (IDYA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, favorable analyst ratings, and upcoming key data readouts that could drive significant upside. While the financials show losses, the revenue growth and promising pipeline make it a compelling long-term opportunity.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. MACD is positive and contracting, suggesting continued bullish momentum. RSI is neutral at 42.124, and the stock is trading near its pivot level of 33.528, with support at 31.813 and resistance at 35.244.
Citi and other analysts have reiterated Buy ratings with price targets as high as $65, citing a favorable setup ahead of the Phase 2/3 OptimUM-02 trial data expected in late March.
IDEAYA's focus on its MTAP-deleted pipeline and promising preclinical results for IDE892 indicate strong potential in oncology.
Revenue growth of 55.37% YoY in Q4 2025 demonstrates strong operational progress.
Net income and EPS declined significantly YoY, reflecting ongoing losses.
No recent insider or hedge fund activity, indicating a lack of strong institutional conviction in the near term.
In Q4 2025, revenue increased by 55.37% YoY to $10.88M, showcasing strong growth. However, net income dropped to -$83.27M (-36.10% YoY), and EPS fell to -0.94 (-36.91% YoY), reflecting ongoing operational losses. Gross margin remained at 100%, indicating efficient cost management.
Analysts are overwhelmingly positive on IDYA, with multiple Buy ratings and price targets ranging from $45 to $65. The upcoming OptimUM-02 trial data is seen as a major catalyst, with a high probability of success and potential upside of 15%-25%.
